- Home
- GLSI vs PAYS Comparison
GLSI vs PAYS Comparison
Compare GLSI & PAYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLSI
- PAYS
- Stock Information
- Founded
- GLSI 2006
- PAYS 2001
- Country
- GLSI United States
- PAYS United States
- Employees
- GLSI N/A
- PAYS N/A
- Industry
- GLSI Biotechnology: Pharmaceutical Preparations
- PAYS Business Services
- Sector
- GLSI Health Care
- PAYS Consumer Discretionary
- Exchange
- GLSI Nasdaq
- PAYS Nasdaq
- Market Cap
- GLSI 133.4M
- PAYS 125.2M
- IPO Year
- GLSI 2020
- PAYS 1998
- Fundamental
- Price
- GLSI $9.39
- PAYS $7.42
- Analyst Decision
- GLSI Strong Buy
- PAYS Strong Buy
- Analyst Count
- GLSI 1
- PAYS 4
- Target Price
- GLSI $39.00
- PAYS $7.06
- AVG Volume (30 Days)
- GLSI 37.8K
- PAYS 722.3K
- Earning Date
- GLSI 08-13-2025
- PAYS 07-30-2025
- Dividend Yield
- GLSI N/A
- PAYS N/A
- EPS Growth
- GLSI N/A
- PAYS N/A
- EPS
- GLSI N/A
- PAYS 0.11
- Revenue
- GLSI N/A
- PAYS $63,792,627.00
- Revenue This Year
- GLSI N/A
- PAYS $30.03
- Revenue Next Year
- GLSI N/A
- PAYS $20.14
- P/E Ratio
- GLSI N/A
- PAYS $65.76
- Revenue Growth
- GLSI N/A
- PAYS 26.77
- 52 Week Low
- GLSI $8.06
- PAYS $1.80
- 52 Week High
- GLSI $18.15
- PAYS $7.25
- Technical
- Relative Strength Index (RSI)
- GLSI 42.26
- PAYS 89.42
- Support Level
- GLSI $8.67
- PAYS $4.72
- Resistance Level
- GLSI $9.37
- PAYS $7.25
- Average True Range (ATR)
- GLSI 0.28
- PAYS 0.39
- MACD
- GLSI 0.00
- PAYS 0.16
- Stochastic Oscillator
- GLSI 28.74
- PAYS 96.86
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.